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 3 
Abstract 32 
 33 
The aim of the present study was to investigate the relationship between the 34 
hydroxytyrosol (HT) dose intake and the HT metabolites tissue uptake in order to assess 35 
if the HT levels detected in tissues after the administration of different doses are 36 
relevant and sufficiently compatible with those that have been reported as in vitro 37 
modulators of biological functions. Rats were given a refined olive oil enriched with HT 38 
at different doses (1, 10 and 100 mg/kg) and after 5 hours they were sacrificed. Plasma 39 
samples and different organs as liver, kidney, heart and brain were obtained, and HT 40 
metabolites were analyzed by UPLC-MS/MS. The results showed that HT and its 41 
metabolites had a dose-dependent response in both the plasma and tissue deposition for 42 
all the organs analyzed. It is noteworthy the appearance of the native bioactive form of 43 
HT in circulation and the accumulation in the liver and kidney. The detection of greater 44 
amounts of HT sulfate conjugates even at nutritionally-relevant human doses indicates 45 
that the bioactivities of these metabolites are also worthy of future research in order to 46 
understand the clinical implications of olive oil phenolics, specially to prevent certain 47 
hepatic and renal diseases. 48 
49 
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 4 
In recent years, hydroxytyrosol (HT) and its derivatives have led to a great interest from 50 
the virgin olive oil (VOO) producers and manufacturers of nutraceutical supplements. 51 
The increasing interest in HT is mainly due to the EFSA Panel on Dietetic Products, 52 
Nutrition and Allergies (NDA) inform that established a cause-and-effect relationship 53 
between the consumption of olive oil polyphenols and protection of LDL particles from 54 
oxidative damage [1]. Based on this positive opinion, the health claim “Olive oil 55 
polyphenols contribute to the protection of blood lipids from oxidative stress” was 56 
included in the list of health claims [2], being the only authorized health claim in the 57 
European Union regarding polyphenols and health.  58 
In relation to the mechanisms by which olive phenolic compounds can exercise 59 
their cardioprotective activity it is becoming more evident that polyphenols exert their 60 
cellular protection by interacting with intracellular signaling pathways involved in 61 
pathological processes [3]. After absorption, plasma proteins can be targets of the 62 
phenolic metabolites, and there are also possible interactions with proteins in specific 63 
target organs in the human body [4]. Therefore, along with the effort to elucidate 64 
molecular targets of HT, knowledge about its organ distribution and tissue uptake may 65 
increase comprehension of its beneficial effects on health. For this, it is necessary to 66 
assess if the HT levels detected in tissues are relevant and sufficiently compatible with 67 
those that have been reported as in vitro modulators of biological functions. In relation 68 
to the metabolism and tissue uptake of HT, previous studies have been performed in 69 
rats, either using intravenously injected [
14
C] hydroxytyrosol [5] or by oral 70 
administration of an olive phenol extract [6]. Although the pharmacokinetic response 71 
and tissue distribution of HT was thoroughly investigated in these aforementioned 72 
studies, no information is available in the literature regarding the dose-dependent uptake 73 
of HT and its main metabolites into target tissues.  74 
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 5 
 In this context, the present study aimed to investigate the relationship between 75 
the HT dose intake and tissue uptake in rats, and thus, providing complementary 76 
information in relation to the target/dose relationship. For this purpose, liver, kidney, 77 
brain and heart were collected after the administration of three different doses: 1 mg 78 
HT/kg rat weight (HT-1) compatible with human dietary habits [7], and two higher 79 
doses (10 mg/kg rat weight: HT-10 and 100 mg/kg rat weight: HT-100) that could 80 
mimic medium and high exposures of HT through dietary supplements. Detailed 81 
materials and methods are contained in the Supporting Information. 82 
 Results of the plasma analysis showed that free HT and its metabolites were 83 
detected and were measurable after the three administered doses (Table 1), except for 84 
the glucuronide conjugates, which were only detected at the highest doses (HT-10 and 85 
HT-100). In the control plasma (vehicle), none of these compounds were detected, 86 
which validates them as products of HT metabolism. Sulfation was the most relevant 87 
conjugation pathway at the three administered doses compared with the glucuronide 88 
conjugates. It is important to highlight that the free form of HT was detected in the 89 
plasma after the administration of all three doses and that the recovery of free HT 90 
appeared to rise in a dose-dependent fashion (from 0.05 µmol/L HT-1 to 12.9 µmol/L 91 
HT-100) as with the metabolites (p trend<0.001).  92 
 The dose effect on the tissue uptake of HT was first studied on two metabolic 93 
tissues (liver, kidney) obtained five hours after the intake of the vehicle (refined olive 94 
oil) and the different doses of HT (Table 2). In general, the nature of the HT 95 
metabolites was similar to the plasma and a significant dose-dependent uptake was 96 
observed for all metabolites studied (p trend<0.001) except for HVAlc in the kidney 97 
(Table 2). Additionally, significant differences were observed for the metabolites 98 
quantified at all HT doses compared to the vehicle group (p<0.001). 99 
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 6 
Interestingly, the free active form of HT was detected in both liver and kidney. If 100 
we compare our results with those that have been reported as in vitro modulators of 101 
biological functions, the concentrations of HT tested in vitro cell lines showed 102 
significant effects in the range of 5-10 µM in the case of kidney [8] and in the range of 103 
1−5 µM for hepatic cell lines [9], which were much higher than those detected in our 104 
study (2-83 nM) (Table 2). Despite that, recent studies have reported that HT possesses 105 
in vivo hepatoprotective effects [10-12]. So it can be hypothesized that HT metabolites 106 
may be active per se, or provide a pool for local or systemic regeneration of HT in vivo. 107 
HT metabolites, which might also show biological activities, probably explain the 108 
modulation of other pathways/mechanisms from than those previously reported related 109 
to direct antioxidant/scavenging mechanisms [8,13]. Indeed, the most recent hypothesis 110 
regarding the mechanism of action of polyphenols is that they can exert protective 111 
effects modulating signal transduction, cell signaling, gene expression and cellular 112 
communication in several pathways [14].  113 
Besides the metabolic tissues, two target tissues (brain and heart) were studied 114 
showing a lower deposition of HT metabolites (Table 3). Regarding the brain, some of 115 
the HT metabolites were also detected in the vehicle group suggesting that the low 116 
concentrations detected could be produced endogenously from dopamine metabolism 117 
[15]. It is remarkable, however, that at the highest dose (HT-100), HT-S, HV-Ac, 118 
HVAc-S and HVAlc-S presented significant increases compared to the other  119 
administered doses, indicating that only at higher doses some metabolites from the HT 120 
intake could cross the blood-brain barrier. In fact, dose-dependent accumulation of HT-121 
S and HVAlc-S was observed in the brain (p trend<0.001) (Table 3). A previous study 122 
reported that the administration of 100 mg/kg of HT in mice enhanced cytoprotection 123 
and the resistance of dissociated brain cells to oxidative stress [16]. Thus, it could be 124 
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 7 
hypothesized that the accumulation of these metabolites in the brain after a 125 
pharmacological dose of HT could exert a neuro-protective activity in the central nerve 126 
system. In the present study, the free form of HT was not detected in the brain, in 127 
contrast to a previous study, in which 100 mg/kg of HT was administered through the 128 
femoral vein [17] and considerable amounts of free HT were detected in the brain. 129 
Compared with the oral route of our study, intravenous administration could explain the 130 
higher exposure of HT to the brain tissue and its detection in its free form. 131 
In contrast to other tissues, HT metabolites were not detected in the heart in HT-1 132 
and HT-10 groups (Table 3), being HT-S the main metabolite quantified after the HT-133 
100. Unlike in the liver and kidney, free HT was not detected in the heart. However, 134 
free HT and its metabolites were detected in plasma even at the nutritionally-relevant 135 
dose (Table 1), which could explain the cardioprotective effects of VOO phenols 136 
previously described at different circulation targets. Reported in vivo studies indicate 137 
that HT can reduce endothelial activation [18], inhibit platelet aggregation [19] and 138 
reduce the plasma-reduced homocysteine concentration [20], effects that have been 139 
associated with cardiovascular protection and could be related to the presence of 140 
circulating HT and its metabolites.  141 
Interestingly, in samples obtained from HT-100 group, a significant gender effect 142 
was observed in the plasma (Table 1), liver and kidney (Table 2). Plasmatic 143 
concentrations of free HT and its main metabolites HT-S and HVAc were significantly 144 
higher (p<0.05) in females (Table 1). Similarly, the concentrations of free HT and 145 
metabolites (HT-S, HVAc, HVAc-S and HVAlc-S) were significantly higher (p<0.05) 146 
in the liver from females, this being the tissue where the gender effect was more striking 147 
(Table 2). No gender effect was observed in the uptake of HT metabolites in the brain 148 
and heart (data not shown). Our results are in line with previous studies in which 149 
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 8 
genistein and daidzein, two major isoflavones in soy, also presented an enhanced oral 150 
bioavailability in females than in males [21]. The main reason that could explain these 151 
differences seems to be the different expression profiles of metabolizing enzymes and 152 
efflux transporters in the main metabolic disposition organs, such as the intestine, liver 153 
and kidney [22]. In other studies, pulsatile versus continuous release of growth hormone 154 
in male and female rats, respectively, has been suggested as a major reason for the sex-155 
dependent differences in the expression profiles of the hepatic phase I metabolizing 156 
enzymes [23]. 157 
Summarizing, our study showed that HT and its metabolites could be accumulated 158 
in a dose-dependent manner basically in the liver, kidney and brain and were detected in 159 
these tissues even at nutritionally-relevant human doses, a dose that was not previously 160 
studied in tissue disposition. The detection of free HT in liver and kidney is noteworthy. 161 
To date, this appears to be the only biologically active form, and thus, it provides 162 
relevant information for optimizing the potential applications of HT to prevent certain 163 
hepatic and renal diseases. However, the detection of greater amounts of HT 164 
metabolites in tissues, specifically the sulfate conjugates, indicates that the bioactivities 165 
of these metabolites are also worthy of future research in order to understand the 166 
clinical implications of olive oil phenolics. The obtained results regarding the 167 
target/dose relationship of HT and its metabolites, together with the literature data on 168 
the biological effects, allow increasing our understanding of the health beneficial effects 169 
of HT. 170 
 171 
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Table 1. Concentration (µmol/L plasma) of HT and its metabolites in rat plasma after 5 255 
hours of the administration of different doses of HT and the vehicle (refined oil). Effect 256 
of gender in plasma concentration at HT-100 dose. 257 
Compound 
(µmol/L) 
Vehicle HT-1  HT-10  
HT-100  
Mean value Male Female 
HT n.d. 0.05 ±0.03
a
 0.99 ± 0.66
a
 12.9 ± 5.05
b
 8.38 ± 4.10* 17.4 ± 8.40* 
HT-S n.d. 0.12 ± 0.05
a
 1.28 ± 0.85
a
 16.5 ± 6.40
b
 9.82 ± 3.82* 22.7 ± 8.40* 
HT 4'-Gluc n.d. n.d. 0.18 ± 0.12
a
 1.87 ± 1.03
b
 1.77 ± 1.13 1.93 ± 0.86 
HT 3'-Gluc n.d. n.d. 0.11 ± 0.10
a
 1.18 ± 0.69
b
 0.91 ± 0.49 1.50 ± 0.68 
HVAc n.d. 0.05 ± 0.09
a 0.53 ± 0.37a 7.65 ± 2.86b 2.87 ± 0.63* 11.2 ± 5.35* 
HVAc-S n.d. 0.28 ± 0.15
a 2.17 ± 1.08a 14.9 ± 5.42b 13.3 ± 5.01 16.6 ± 5.83 
HVAlc n.d. 0.12 ± 0.09
a 0.14 ± 0.10a 0.18 ± 0.16a 0.09 ± 0.09 0.25 ± 0.17 
HVAlc-S n.d. 0.09 ± 0.03
a 0.38 ± 0.16b 2.21 ± 1.09c 2.32 ± 0.65 2.16 ± 1.26 
HVAlc-Gluc n.d. n.d. 0.12 ± 0.06
a
 0.57 ± 0.32
b
 0.74 ± 0.43 0.48 ± 0.18 
HT: hydroxytyrosol; HT-S: hydroxytyrosol-sulfate; HT 4-Gluc: hydroxytyrosol 4’ glucuronide; 258 
HT 3-Gluc: hydroxytyrosol 3’ glucuronide; HVAc: homovainillic acid; HVAc-S: homovainillic acid-sulfate; 259 
HVAlc: homovainillic alcohol; HVAlc-S: homovainillic alcohol-sulfate; HVAlc-Gluc: homovainillic alcohol-260 
glucuronide. 261 
 262 
Values are mean ± SD (n=8). Values male and female are mean ± SD (n=4). 263 
abc 
mean significant differences between doses in the same row (p< 0.001) 264 
*  mean significant differences between genders in the same row of HT-100 (p< 0.05) 265 
n.d. not detected 266 
267 
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Table 2. Concentration (nmol/g fresh tissue) of HT and its metabolites in rat metabolic 268 
tissues (liver and kidney) after 5 hours of the administration of different doses of HT 269 
and the vehicle (refined oil). Effect of gender in the tissue disposition at HT-100 dose. 270 
Compound 
(nmol/g fresh 
tissue) 
LIVER 
Vehicle HT-1 HT-10 
HT-100 
Mean value Male Female 
HT n.d. 0.1 ± 0.01
a
 1.11 ± 0.59
a
 17.5 ± 12.9
b
 7.66 ± 1.68* 27.4 ± 11.5* 
HT-S n.d. 0.02 ± 0.01
a
 1.26 ± 0.70
a
 27.4 ± 26.5
b
 8.76 ± 1.84* 46.1 ± 26.6* 
HT 4-Gluc n.d. n.d. n.d. 0.21 ± 0.09
 
 0.16 ± 0.12 0.26 ± 0.03 
HT 3-Gluc n.d. n.d. n.d. 0.22 ± 0.14
 
 0.14 ± 0.07 0.31 ± 0.14 
HVAc n.d. n.d. 0.03 ± 0.05
a
 2.67 ± 3.20
b
 0.50 ± 0.17* 4.85 ± 3.46* 
HVAc-S n.d. 0.04 ± 0.02 0.56 ± 0.33
a
 6.71 ± 3.28
b
 4.92 ± 3.65* 8.49 ± 1.63* 
HVAlc n.d. n.d. n.d. n.d. n.d. n.d. 
HVAlc-S n.d. n.d. 0.32 ± 0.13
a
 5.23 ± 5.28
b
 1.80 ± 0.27* 8.66 ± 5.74* 
HVAlc-Gluc n.d. n.d. n.d. 0.04 ± 0.03 0.02 ± 0.01 0.07 ± 0.02 
Compound 
(nmol/g fresh 
tissue) 
KIDNEY 
Vehicle HT-1 HT-10 
HT-100 
Mean value Male Female 
HT n.d. n.d. 2.73 ± 2.33
a
 33.9 ± 10.3
b
 26.1 ± 3.28* 41.8 ± 10.3* 
HT-S 0.14 ± 0.16
a
 0.48 ± 0.1
a
 10.1 ± 5.74
b
 82.8 ± 38.9
c
 78.9 ± 5.70 86.8 ± 29.7 
HT 4-Gluc n.d. 0.02 ± 0.05
a
 0.25 ± 0.12
b
 0.89 ± 0.39
c
 0.88 ± 0.09 1.09 ± 0.10 
HT 3-Gluc n.d. 0.02 ± 0.05
a
 0.25 ± 0.12
b
 0.99 ± 0.45
c
 0.94 ± 0.07 1.04 ± 0.31 
HVAc 0.26 ± 0.17
a
 0.33 ± 0.13
a
 1.26 ± 0.76
b
 7.90 ± 2.25
c
 6.73 ± 2.89 9.07 ± 1.65 
HVAc-S 1.22 ± 0.51
a
 0.98 ± 0.31
a
 2.32 ± 0.74
b
 6.90 ± 1.33
c
 8.49 ± 2.98 5.30 ± 0.05 
HVAlc 0.23 ± 0.27
a
 0.21 ± 0.22
a
 0.46 ± 0.17
b
 0.30 ± 0.30
a
 0.20 ± 0.23 0.40 ± 0.01 
HVAlc-S 0.26 ± 0.02
a
 0.45 ± 0.09
a
 3.23 ± 1.38
b
 20.1 ± 4.98
c
 19.3 ± 4.63 21.9 ± 12.7 
HVAlc-Gluc n.d. 0.14 ± 0.03
a
 0.22 ± 0.03b 0.39 ± 0.06c 0.37 ± 0.10 0.41 ± 0.07 
HT: hydroxytyrosol; HT-S: hydroxytyrosol-sulfate; HT 4-Gluc: hydroxytyrosol 4’ glucuronide; 271 
HT 3-Gluc: hydroxytyrosol 3’ glucuronide; HVAc: homovainillic acid; HVAc-S: homovainillic acid-sulfate; 272 
HVAlc: homovainillic alcohol; HVAlc-S: homovainillic alcohol-sulfat ; HVAlc-Gluc: homovainillic 273 
alcohol-glucuronide. 274 
 275 
Values are mean ± SD (n=8). Values male and female are mean ± SD (n=4). 276 
abc 
mean significant differences between doses in the same row (p< 0.001) 277 
*  mean significant differences between genders in the same row of HT-100 (p< 0.05) 278 
n.d. not detected 279 
280 
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Table 3. Concentration (nmol/g fresh tissue) of HT and its metabolites in rat 281 
target tissues (heart and brain) after 5 hours of the administration of 282 
different doses of HT and the vehicle (refined oil). 283 
Compound 
(nmol/g fresh tissue) 
BRAIN 
Vehicle HT-1 HT-10 HT-100 
HT n.d. n.d. n.d. n.d. 
HT-S 0.26 ± 0.00
 a
 0.32 ± 0.05
 a
 0.35 ± 0.10
 a
 1.26 ± 0.72 
b
 
HT 4-Gluc n.d. n.d. n.d. 0.14 ± 0.03 
HT 3-Gluc n.d. n.d. n.d. 0.15 ± 0.02 
HVAc 0.34 ± 0.01
 a 0.39 ± 0.04
 a
 0.32 ± 0.02
 a 0.40 ± 0.05 b 
HVAc-S 0.50 ± 0.03
 a
 0.72 ± 0.10 
b
 0.49 ± 0.08
 a
 0.58 ± 0.12
 b
 
HVAlc n.d n.d. n.d. n.d. 
HVAlc-S 0.14 ± 0.08
 a
 0.22 ± 0.01
 a
 0.41 ± 0.12
 b 2.58 ± 1.26 c 
HVAlc-Gluc n.d. n.d. n.d. n.d. 
Compound 
(nmol/g fresh tissue) 
HEART 
Vehicle HT-1 HT-10 HT-100 
HT n.d. n.d. n.d. n.d 
HT-S n.d. n.d. n.d. 2.73 ± 2.19 
HT 4-Gluc n.d. n.d. n.d. 0.02 ± 0.02 
HT 3-Gluc n.d. n.d. n.d n.d 
HVAc n.d. n.d. n.d. 0.08 ± 0.10 
HVAc-S n.d. n.d. n.d. 0.19 ± 0.22 
HVAlc n.d. n.d. n.d. n.d 
HVAlc-S n.d. n.d. n.d. 0.42 ± 0.33 
HVAlc-Gluc n.d. n.d. n.d. n.d 
HT: hydroxytyrosol; HT-S: hydroxytyrosol-sulfate; HT 4-Gluc: ydroxytyrosol 4’ glucuronide; 284 
HT 3-Gluc: hydroxytyrosol 3’ glucuronide; HVAc: homovainillic acid 285 
HVAc-S: homovainillic acid-sulfate; HVAlc: homovainillic alcohol; 286 
HVAlc-S: homovainillic alcohol-sulfate; HVAlc-Gluc: homovainillic alcohol-glucuronide 287 
 288 
Values are mean ± SD (n=8).  289 
abc 
mean significant differences between doses in the same row (p< 0.001). 290 
n.d. not detected 291 
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